Clinical observation of interferon as a basis for individual roadmap for treating HBeAg positive chronic hepatitis B
Xiao-yi FU,Xiu-feng ZHANG,Hai-hua LIN,Yan-zhong PENG
DOI: https://doi.org/10.3969/j.issn.1674-7380.2014.02.007
2014-01-01
Abstract:Objective To observe treatment of HBeAg positive chronic hepatitis B with individual antiviral efifcacy and drug price roadmap. To look for a suitable, effective and inexpensive treatment. Methods After patients are informed consent, 66 eligible patients, were divided into individual group 36, control group 30. Individual group is treated according to the roadmap treatment, the control group with interferon and entecavir treatment initially. The biochemical, virological, serological indicators at week 24, week 48, week 72 and week 24 after drug withdrawal were evaluated, response efifcacy was compared withχ2 test. Results HBsAg negative rate, HBeAg negative conversion rate, HBV DNA seroconversion rates of individual group and control group at week 24 were 11.1%, 27.8%, 38.9%and 16.7%, 40.8%, 96.7%, the control group was better than the individual group. But at week 72, HBsAg negative rate, HBeAg negative conversion rate, HBV DNA seroconversion rates of individual group and control were 30.6%, 69.4%, 97.2%and 20%, 43.3%, 93.3%. There is signiifcant difference between two groups HBeAg (P<0.05), individual group and the control group, the average cost of drugs are (20000 ± 5000) yuan and (30000 ± 5000) yuan. Conclusions The use of individual road map plan to the treatment of HBeAg positive chronic hepatitis B can improve HBsAg, HBeAg negative conversion rate, but also save the cost of drugs, but it is need randomized clinical trials for larger sample size to prove.